


Appendix/Supplementary material**Figure S1: Viral load set point by HSV-2 serostatus in vaccine and placebo HIV seroconverters**

Appendix Table 1: Univariate logistic regression analysis of baseline factors associated with baseline HSV-2 sero-status

Baseline factor	Prevalence of the baseline factor in the study cohort (%)	Odds ratio	95% Lower-bound	95% Upper-bound	Univariate p-value
Male circumcision (circumcised)	56	0.28	0.24	0.33	<0.001
Race (White)	49	0.27	0.23	0.31	<0.001
Age younger than 30 years	53	0.32	0.28	0.37	<0.001
North America and Australia region	65	0.31	0.27	0.35	<0.001
Ad5 titer greater than 18	58	0.53	0.47	0.61	<0.001
STD (yes)	3	0.83	0.48	1.42	0.49
GUD (yes)	0.7	3	0.9	13.52	0.1
Risk behaviors (6 months prior to enrollment)					
Any Drug use	27	0.39	0.32	0.48	<0.001
POPPERS use	7	0.46	0.32	0.66	<0.001
SPEED use	3	0.4	0.21	0.73	0.004
Number of male partners (>4)	17	0.77	0.61	0.96	0.02
Unprotected receptive anal sex with HIV positive partner (yes)	2	0.44	0.21	0.87	0.02
Unprotected receptive anal sex with HIV-negative partner (yes)	11	0.45	0.33	0.6	<0.001
Unprotected receptive anal sex with HIV-negative partner (yes)	11	0.71	0.53	0.94	0.02
Unprotected insertive anal sex with HIV positive partner (yes)	5	0.44	0.28	0.69	<0.001
Unprotected insertive anal sex with HIV-negative partner (yes)	13	0.32	0.24	0.43	<0.001
Unprotected insertive anal sex with HIV-negative partner (yes)	22	0.43	0.33	0.57	<0.001
Unprotected receptive anal sex regardless of partners' HIV sero-status (yes)	22	0.57	0.46	0.7	<0.001
Unprotected insertive anal sex regardless of partners' HIV sero-status (yes)	27	0.36	0.3	0.44	<0.001